Genotype-guided dosing of warfarin

Clinical Chemistry

Volumn 60, Issue 7, 2014, Pages 920-922

  Mega, Jessica L ^a   Giugliano, Robert P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; VITAMIN K EPOXIDE REDUCTASE; WARFARIN;

ALGORITHM; DRUG METABOLISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEREDITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; PHARMACOGENETICS; REVIEW; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; VENOUS THROMBOEMBOLISM; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84903723050     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.220004     Document Type: Review

References (4)

1. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011;90:625-9.
2. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013;369:2294-303.
3. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013;369:2283-93.
4. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials. Lancet 2014;383:955-62.